Preclinical studies suggest that fenofibrate and other PPARα agonists may reduce the risk of HF through multiple mechanisms, including preservation of myocardial energy metabolism, attenuation of inflammation and oxidative stress, reduction of fibrosis, and protection against ischaemic injury. The gene discussed is PPARA; the disease is hydrops fetalis.